BioSpace News Archive

Drug Development

Clinical Catch-Up: November 22-26

Thanksgiving week was marked by numerous clinical trial announcements. Here’s a look.

November 26, 2021
·
6 min read
·
Mark Terry
FDA

FDA Action Alert: Legend & Janssen, Merck & Ridgeback, Amryt, BeyondSpring and More

The U.S. Food and Drug Administration has a very busy calendar for the end of November and beginning of December. Here’s a look.

November 26, 2021
·
5 min read
·
Mark Terry
Drug Development

Starpharma releases positive DEP® phase 2 interim results in prostate cancer

Melbourne biotech company Starpharma announced positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel.

November 26, 2021
·
4 min read
Drug Development

Ocugen, Inc. Provides an Update on its Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)

Ocugen, Inc. announced that the U.S. Food and Drug Administration has issued a clinical hold on the Company’s Investigational New Drug application to evaluate the COVID-19 vaccine candidate, BBV152, known as COVAXIN™ outside the United States.

November 26, 2021
·
7 min read
Pharm Country

Enzychem to Partner with Zydus Cadila to Manufacture COVID-19 Plasmid DNA Vaccine in Korea

Enzychem Lifesciences and Cadila Healthcare Ltd, a part of the Zydus Group, announced that they have entered a Manufacturing License and Technology Transfer Agreement for the world’s first plasmid DNA vaccine.

November 26, 2021
·
3 min read
Policy

Statement from the Chief Public Health Officer of Canada on November 26, 2021

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

November 26, 2021
·
7 min read
Lysogene Secures a €4.3 Million Non-dilutive Financing From Bpifrance to Support Its Development

Lysogene, a phase 3 gene therapy platform Company targeting central nervous system diseases, announced that it has secured a €4.3 million non-dilutive financing from Bpifrance.

November 26, 2021
·
4 min read
BioMidwest

Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19

Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics provided an update on the MOVe-OUT study of molnupiravir, an investigational oral antiviral medicine for COVID-19.

November 26, 2021
·
7 min read
Business

Can-Fite Reports Third Quarter 2021 Financial Results & Provides Clinical Update

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced financial results for the quarter ended September 30, 2021.

November 26, 2021
·
11 min read
Drug Development

QuantuMDx confirm its diagnostic tests remain able to detect all known variants of COVID-19 including the new variant from South Africa, B.1.1.529

QuantuMDx Group Limited, confirms that both its SARS-CoV-2 assays for open PCR platforms and its rapid PCR device, Q-POC™, as well as its future respiratory panel, remain able to detect all known virus strains, including the latest variant, B.1.1.529.

November 26, 2021
·
2 min read